Another company has chosen to add Bitcoin (BTC) to its balance.
Christian Angermayer, president of the Biopharmaceutical Company based in Germany, Atai Life Sciences (ATAI), announced today that the company would develop its own Bitcoin Treasury strategy.
“In an era of persistent inflation and volatile markets, I find myself asking an important question for biotechnology companies that seek to preserve and optimize the capital they have: it could assign a part of the treasure cash to the help of Bitcoin preserve, optimize and even extend the clue to pass the track of a company and, therefore, contribute to their success,” Angermayer wrote in replacement.
Initially, the company will invest $ 5 million in Bitcoin, Angemayer said, while having enough cash, short -term values and public capital for operating expenses in 2027.
The pharmaceutical firm is the last of a long line of corporations that have tried to replicate the Bitcoin Treasury strategy of Michael Saylor.
Atai briefly increased when the news occurred, but now it has dropped 2.8% for the day. After briefly exceeding $ 87,000 during the night, Bitcoin has been in fast withdrawal, now changing from hands to $ 83,900, lower by approximately 1% in the last 24 hours.
